X-连锁低血磷性佝偻病的治疗现状及展望

doi:10.11852/zgetbjzz2020-1919

中国儿童保健杂志 ›› 2021, Vol. 29 ›› Issue (11): 1223-1227.DOI: 10.11852/zgetbjzz2020-1919

X-连锁低血磷性佝偻病的治疗现状及展望

李文鑫, 任立红

哈尔滨医科大学附属第二医院儿科,黑龙江哈尔滨 150081

收稿日期:2020-11-02 修回日期:2021-03-14 发布日期:2021-11-05 出版日期:2021-11-10
通讯作者: 任立红,E-mail:renlihong1@126.com
作者简介:李文鑫(1994-),女,山东人,在读硕士研究生,主要研究方向为儿童保健。

Current situation and prospect of X-linked hypophosphatemia rickets

LI Wen-xin, REN Li-hong

Department of Pediatrics, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081,China

Received:2020-11-02 Revised:2021-03-14 Online:2021-11-10 Published:2021-11-05
Contact: REN Li-hong, E-mail:renlihong1@126.com

摘要/Abstract

摘要： X-连锁低血磷性佝偻病(XLH)属于遗传性代谢性骨病,发病机制复杂,在临床上较为罕见,其主要临床表现为骨骼畸形及身材矮小,致残率高,因而针对XLH进行及早诊断及治疗对患者康复具有极为重要的意义。传统治疗以补充磷酸盐和维生素D类似物为主,随着学者对XLH病理机制研究逐渐深入,分子靶向治疗等新型治疗方式横空出世,通过多学科联合诊断及治疗的方法为患者带去了福音。本文就XLH的临床特征、发病遗传机制、治疗现状及治疗的未来发展趋势进行综述。

关键词: X-连锁低血磷性佝偻病, 临床特征, 发病遗传机制, 治疗方法

Abstract: X-linked hypophosphatemia rickets(XLH) is a hereditary metabolic bone disease with a complex pathogenesis and is relatively rare clinically. Its main clinical manifestations are skeletal malformation and short stature with a high disability rate. Therefore, early diagnosis and treatment of XLH is of great significance to the rehabilitation of patients. Traditional treatment mainly focuses on supplementing phosphate and vitamin D analogue. With the gradual deepening of scholars′ research on the pathological mechanism of XLH, new therapeutic methods such as molecular targeted therapy have emerged, bringing good news to patients through multidisciplinary joint diagnosis and treatment. In this paper, the clinical characteristics, pathogenesis, treatment status and future development trend of XLH will be reviewed.

Key words: X-linked hypophosphatemia rickets, clinical features, genetic mechanism, treatment

中图分类号:

R723.2

李文鑫, 任立红. X-连锁低血磷性佝偻病的治疗现状及展望[J]. 中国儿童保健杂志, 2021, 29(11): 1223-1227.

LI Wen-xin, REN Li-hong. Current situation and prospect of X-linked hypophosphatemia rickets[J]. Chinese Journal of Child Health Care, 2021, 29(11): 1223-1227.

参考文献

[1] Sammut J,Imbroll MG,Gruppetta M.X-linked hypophosphatemic rickets:the challenges of treatment[J]. Clinic Rev Bone Miner Metab,2019,17:138-141.
[2] Haffner D,Emma F,Eastwood DM,et al.Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia[J]. Nat Rev Nephrol,2019,15(7):435-455.
[3] Jessica C,Olear EA,Insogna KL,et al.Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease[J]. J Clin Endocrinol Metab,2015,100(10):3625-3632.
[4] 李丽丽,刘冬云,邵光花,等. 新生儿期诊断伴X染色体遗传低磷性维生素D佝偻病并一家系3例报告[J]. 中国儿童保健杂志,2019,27(2):230-232.
[5] Colares Neto GP,Ide Yamauchi F,Hueb Baroni R,et al.Nephrocalcinosis and nephrolithiasis in X-linked hypophosphatemic rickets: diagnostic imaging and risk factors[J]. J Endocr Soc,2019,3(5):1053-1061.
[6] Li SS,Gu JM,Yu WJ,et al. Seven novel and six de novo PHEX genemutations in patients with hypophosphatemie ricets[J]. Int J Mol Med,2016,38(6):1703-1714.
[7] Carpenter TO,Whyte MP,Imel EA,et al. Burosumab therapy in children with X-linked hypophosphatemia[J]. N Engl J Med,2018,378(21):1987-1998.
[8] Beck-Nielsen SS,Mughal Z,Haffner D,et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity[J]. Orphanet J Rare Dis,2019,14(1):58.
[9] Zheng B,Wang C,Chen Q,et al. Functional characterization of PHEX gene variants in children with X-linked hypophosphatemic rickets shows no evidence of genotype-phenotype correlation[J]. J Bone Miner Res,2020,35(9):1718-1725.
[10] 李媛,马小雪.家族性低磷血症性佝偻病家系X染色体内肽酶同源性的磷酸调节基因新突变一例报道[J].中国全科医学,2018(2):3010-3014.
[11] 李恬恬,张立琴.X-连锁低血磷性抗维生素D佝偻病基因突变研究进展[J].中国儿童保健杂志,2017,25(12):1233-1235.
[12] 张丛,赵真,许莉军,等. X-连锁显性低血磷性佝偻病/骨软化症患者血清成纤维细胞生长因子23水平[J].中华骨质疏松和骨矿盐疾病杂志,2019,12(1):24-31.
[13] 周倩.低磷性佝偻病研究进展[J]. 国际儿科学杂志,2018,45(2):129-132,136.
[14] Kinoshita Y,Fukumoto S.X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases-prospect for new treatment[J].Endocr Rev,2018,39(3):274-291.
[15] 李振彪,张继要,董伟,等.家族性低磷性抗维生素D佝偻病4个家系PHEX、FGF-23、DMP-I基因突变分析[J].中华实用儿科临床杂志,2015,30(20):1549-1553.
[16] Clinkenbeard EL,White KE.Systemic control of bone homeostasis by FGF23 signaling[J]. Curr Mol Biol Rep,2016,2(1):62-71.
[17] Takashi Y,Fukumoto S.Phosphate-sensing and regulatory mechanism of FGF23 production[J].J Endocrinol Invest,2020,43(7):877-883.
[18] Fukumoto S. FGF23-FGF receptor/Klotho pathway as a new drug target for disorders of bone and mineral metabolism[J].Caleif Tissue Int,2016,98(4):334-340.
[19] 殷常瑜,郭伟韬,王怀波,等.X-连锁低血磷性佝偻病发病遗传机制[J].国际医药卫生导报,2020,26(7):916-921.
[20] 莫湘涛.股骨头坏死愈胶囊与双磷酸盐治疗股骨颈移位骨折术后股骨头缺血性坏死临床研究[J].新中医,2020,52(18):89-91.
[21] Kaneko I,Segawa H,Tatsumi S,et al.Genetic diseases of renal phosphate handling[J].Nihon Jinzo Gakkai Shi,2015,57(4):758-765.
[22] Carpenter TO,Imel EA,Holm IA,et al. A clinician′s guide to X-linked hypophosphatemia[J]. J Bone Miner Res,2011,26(7):1381-1388.
[23] Nickolas TL,Jamal SA.Bone kidney interactions[J].Rev Endocr Metab Disord,2015,16(2):157-163.
[24] 张偲,罗小平.低磷抗维生素D性佝偻病诊治进展[J].中国实用儿科杂志,2017,32(9):669-672,674.
[25] 王青青,薛颖.遗传性低磷血症性佝偻病简述[J/OL].发育医学电子杂志,2020,8(3):277-281.
[26] Haffner D,Nssel R,Wihl E,et al. Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets[J]. Pediatries,2004,113(06):593-596.
[27] Imel EA,Zhang X,Ruppe MD,et al.Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23[J].J Clin Endocrinol Metab,2015,100(7):2565-2573.
[28] Gizard A,Rothenbuhler A,Pejin Z,et al.Outcomes of orthopedic surgery in a cohort of 49 patients with X-linked hypophosphatemic rickets(XLHR)[J].Endocr Connect,2017,6(8):566-573.
[29] Lamb YN.Burosumab:first global approval[J].Drugs,2018,78(6):707-714.
[30] Rothenbuhler A,Schnabel D,Högler W,et al. Diagnosis,treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH)[J]. Metabolism,2020. doi:10.1016/j.metabol.2019.03.009
[31] Carpenter TO,Whyte MP,Imel EA,et al.Burosumab therapy in children with X-linked hypophosphatemia[J]. N Engl J Med,2018,378(21):1987-1998.
[32] Whyte MP,Carpenter TO,Gottesman GS,et al.Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia:a multicentre,open-label,phase 2 trial[J].Lancet Diabetes Endocrinol,2019,7(3):189-199.
[33] Insogna KL,Briot K,Imel EA,et al. A randomized,double-blind,placebocontrolled,phase 3 trial evaluating the efficacy of burosumab,an anti-FGF23 antibody,in adults with X-linked hypophosphatemia:week 24 primary analysis[J].J Bone Miner Res,2018,33(8):1383-1393.

X-连锁低血磷性佝偻病的治疗现状及展望

Current situation and prospect of X-linked hypophosphatemia rickets

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张颖, 王俊峰, 丁艳华. 儿童语言发育迟缓的临床特征和影响因素研究[J]. 中国儿童保健杂志, 2022, 30(8): 912-915.
[2]	张雅如, 张婷, 邵智. 孤独症谱系障碍儿童自我发展的特征及对临床康复的启示[J]. 中国儿童保健杂志, 2022, 30(11): 1212-1215.
[3]	楼丹丹, 徐尔迪, 肖延风. 儿童甲型和乙型流行性感冒早期血常规特征分析[J]. 中国儿童保健杂志, 2020, 28(8): 931-935.
[4]	单延春, 杨召川, 冉霓, 傅芃, 刘小梅, 马良, 冯雪英, 衣明纪. X-连锁低磷佝偻病一家系报道并文献复习[J]. 中国儿童保健杂志, 2019, 27(7): 807-809.
[5]	陈玉霞,詹学. 住院婴幼儿847例中重度营养不良的临床特征分析[J]. 中国儿童保健杂志, 2019, 27(3): 326-329.
[6]	王爱丽, 张惠琴, 张静静, 曹玉红, 张月萍. 105例急性中毒患儿临床特征分析[J]. 中国儿童保健杂志, 2018, 26(8): 909-912.
[7]	胡根彪, 王红丽, 文革生. WASP基因新发突变致Wiskott-Aldrich综合征1例并文献复习[J]. 中国儿童保健杂志, 2018, 26(5): 529-532.
[8]	万瑞平, 吴燕玲, 李小莉, 李安芳, 刘志刚. Ⅰ型脊肌萎缩症患儿6例早期临床特征分析[J]. 中国儿童保健杂志, 2018, 26(3): 341-343.
[9]	魏升云,汤淑斌,张惠,韩鹏,王莉. 宝鸡地区小儿肺炎4 583例临床特征分析[J]. 中国儿童保健杂志, 2017, 25(8): 854-856.
[10]	王召阳, 邢嬛, 申春平, 闫琦, 马琳. 北京市海淀区2 177例42 d婴儿皮肤病临床特征[J]. 中国儿童保健杂志, 2017, 25(5): 516-519.
[11]	王吉,梁亚勇,唐春,李建英,邹小兵. 婴幼儿孤独症的早期预警信号[J]. 中国儿童保健杂志, 2017, 25(3): 242-244.
[12]	蒋英,周亮. 先天性室间隔缺损892例临床特征分析[J]. 中国儿童保健杂志, 2017, 25(1): 73-76.
[13]	刘雪妍,王敏,姜春明. 新生儿Prader-Willi综合征1例及文献复习[J]. 中国儿童保健杂志, 2016, 24(6): 670-672.
[14]	车财妍,韦勇宁. 宁波市654例小儿麻疹流行病学及临床特征分析[J]. 中国儿童保健杂志, 2016, 24(1): 103-104.
[15]	徐亚琴, 梁沂, 胡小沙, 池霞, 郭锡熔, 童梅玲. 儿童功能性构音障碍21个词首辅音的临床特征分析[J]. 中国儿童保健杂志, 2015, 23(5): 472-474.